Integrative genome analysis of somatic p53 mutant osteosarcomas identifies Ets2-dependent regulation of small nucleolar RNAs by mutant p53 protein

被引:50
作者
Pourebrahim, Rasoul [1 ]
Zhang, Yun [1 ]
Liu, Bin [1 ]
Gao, Ruli [1 ]
Xiong, Shunbin [1 ]
Lin, Patrick P. [2 ]
McArthur, Mark J. [3 ]
Ostrowski, Michael C. [4 ]
Lozano, Guillermina [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Genet, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Orthoped Oncol, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Vet Med & Surg, Houston, TX 77030 USA
[4] Ohio State Univ, Dept Canc Biol & Genet, Columbus, OH 43210 USA
基金
美国国家卫生研究院;
关键词
p53; osteosarcoma; snoRNA; metastasis; Ets2; MOUSE MODEL; CANCER; CELLS; GAIN; SURVIVAL; MUTATION; RB; DIFFERENTIATION; TRANSCRIPTION; INACTIVATION;
D O I
10.1101/gad.304972.117
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
TP53 is the most frequently mutated gene in human cancer. Many mutant p53 proteins exert oncogenic gain-of-function (GOF) properties that contribute to metastasis, but the mechanisms mediating these functions remain poorly defined in vivo. To elucidate how mutant p53 GOF drives metastasis, we developed a traceable somatic osteosarcoma mouse model that is initiated with either a single p53 mutation (p53R172H) or p53 loss in osteoblasts. Our study confirmed that p53 mutant mice developed osteosarcomas with increased metastasis as compared with p53-null mice. Comprehensive transcriptome RNA sequencing (RNA-seq) analysis of 16 tumors identified a cluster of small nucleolar RNAs (snoRNAs) that are highly up-regulated in p53 mutant tumors. Regulatory element analysis of these deregulated snoRNA genes identified strong enrichment of a common Ets2 transcription factor-binding site. Homozygous deletion of Ets2 in p53 mutant mice resulted in strong down-regulation of snoRNAs and reversed the prometastatic phenotype of mutant p53 but had no effect on osteosarcoma development, which remained 100% penetrant. In summary, our studies identify Ets2 inhibition as a potential therapeutic vulnerability in p53 mutant osteosarcomas.
引用
收藏
页码:1847 / 1857
页数:11
相关论文
共 50 条
  • [1] Ets2 anchors the prometastatic function of mutant p53 in osteosarcoma
    Liu, Daniel D.
    Kang, Yibin
    GENES & DEVELOPMENT, 2017, 31 (18) : 1823 - 1824
  • [2] Regulation of Mutant p53 Protein Expression
    Vijayakumaran, Reshma
    Tan, Kah Hin
    Miranda, Panimaya Jeffreena
    Haupt, Sue
    Haupt, Ygal
    FRONTIERS IN ONCOLOGY, 2015, 5
  • [3] Mutant p53 and ETS2, a Tale of Reciprocity
    Martinez, Luis Alfonso
    FRONTIERS IN ONCOLOGY, 2016, 6
  • [4] Mutant p53 cooperates with ETS2 to promote etoposide resistance
    Do, Phi M.
    Varanasi, Lakshman
    Fan, Songqing
    Li, Chunyang
    Kubacka, Iwona
    Newman, Virginia
    Chauhan, Krishna
    Daniels, Silvano Rakeem
    Boccetta, Maurizio
    Garrett, Michael R.
    Li, Runzhao
    Martinez, Luis A.
    GENES & DEVELOPMENT, 2012, 26 (08) : 830 - 845
  • [5] Transcription regulation by mutant p53
    L Weisz
    M Oren
    V Rotter
    Oncogene, 2007, 26 : 2202 - 2211
  • [6] Transcription regulation by mutant p53
    Weisz, L.
    Oren, M.
    Rotter, V.
    ONCOGENE, 2007, 26 (15) : 2202 - 2211
  • [7] Small molecules that reactivate mutant p53
    Bykov, VJN
    Selivanova, G
    Wiman, KG
    EUROPEAN JOURNAL OF CANCER, 2003, 39 (13) : 1828 - 1834
  • [8] Antitumor Drugs Targeting Mutant p53 Protein
    Wang, Ruo-Ya
    Zhang, Yuan
    Zhang, Ji-Hong
    Yu, Fei
    PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS, 2024, 51 (01) : 33 - 46
  • [9] Mutant p53 reactivation by small molecules makes its way to the clinic
    Bykov, Vladimir J. N.
    Wiman, Klas G.
    FEBS LETTERS, 2014, 588 (16): : 2622 - 2627
  • [10] Iron regulatory protein 2 is a suppressor of mutant p53 in tumorigenesis
    Zhang, Yanhong
    Feng, Xiuli
    Zhang, Jin
    Chen, Minyi
    Huang, Eric
    Chen, Xinbin
    ONCOGENE, 2019, 38 (35) : 6256 - 6269